Accord received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...

Benefits advisors need to stay proactive and help their clients leverage formulary design, clinical oversight, and ...

The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate ...

Number 5: Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in ...

The APPA, if passed into law, puts an upper limit of 20 patents, but only of certain types of patents (see below), that can be asserted in a BPCIA litigation (the APPA does not affect ANDA litigations ...

Amneal Pharmaceuticals (AMRX) announced that three large insurance coverage accounts, the Veterans Administration, UnitedHealthcare (UNH) and ...

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with ...

Organon and Shanghai Henlius Biotech have announced that the European Medicines Agency (EMA) has validated a marketing ...

Osvyrti ®– Bone / Osteoporosis (60mg Pre-Filled Syringe) Jubereq ®– Oncology (120mg Vial) Joe Dunford, Accord's Vice ...